NervGen Pharma Corp.

Sector

Medical

Primary Exchange/Symbol

TSX.V:NGEN

Listing By Way Of

IPO

Shares Issued, Outstanding

27,200,000

Investor Information

Bill Radvak is a co-founder of NervGen and has been the CEO and director of multiple startup companies. He was a founder and the CEO of Response Biomedical, a publicly listed medical device company, which he led from its inception to a 90-employee, sales and manufacturing company. 778-888-4101 bradvak@nervgen.com

Nature Of The business

NervGen is restoring life's potential by creating innovative solutions for the treatment of nerve damage. Its core technology targets protein tyrosine phosphatase sigma (PTPσ), a neural receptor that impedes nerve regeneration. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various medical conditions. NervGen is advancing a drug candidate into the clinic initially for the treatment of spinal cord injury while leveraging the technology to identify additional therapeutic candidates for other related medical conditions.